Sulfamethoxazole blocks dihydropteroate synthase, an enzyme crucial for folic acid synthesis in bacteria. This halts the production of tetrahydrofolic acid, a vital coenzyme for nucleotide biosynthesis.
Trimethoprim inhibits dihydrofolate reductase, the next enzyme in the folic acid pathway. This further blocks tetrahydrofolic acid production, amplifying the effect of sulfamethoxazole.
The combined action creates a synergistic effect. Individually, these drugs exhibit modest inhibitory power. Together, they achieve significantly stronger bacterial growth suppression, reducing the risk of resistance development.
Specifically, trimethoprim’s inhibition of dihydrofolate reductase prevents the conversion of dihydrofolic acid to tetrahydrofolic acid–a reaction already hampered by sulfamethoxazole’s blockage of dihydropteroate synthase. This sequential inhibition drastically reduces bacterial folic acid levels.
This synergistic mechanism results in a higher antimicrobial potency compared to either drug used alone at the same concentrations. This increased potency allows for lower dosages, reducing the potential for side effects. The sequential blockade also makes resistance development considerably more challenging for bacteria.
